On Target Laboratories Announces FDA Approval of CYTALUX™ (pafolacianine) injection for Identification of Ovarian Cancer During Surgery
Retrieved on:
Monday, November 29, 2021
Patient, Ovarian cancer, Regulation of tobacco by the U.S. Food and Drug Administration, Folate, Cancer, Skin, Nausea, Indigestion, Technology, Lung cancer, Company, Perelman School of Medicine at the University of Pennsylvania, Surgeon, Palpation, Woman, Drug discovery, Priority review, NRG, Target, Doctor of Philosophy, Allergy, Obstetrics, University, Abdominal pain, Pregnancy, Cytoreductive surgery, Gynecologic Oncology (journal), Adult, Gynaecology, Lymph, Fast Track, Laboratory, Vomiting, Miscarriage, FDA, Purdue University College of Pharmacy, Nursing, and Health Sciences, Uncertainty, Associate, Multimedia, Flushing, Pain scale, Center, Itch, Birth, Food, Pharmaceutical industry, Birth control, Dairy product, Medical imaging
CYTALUX is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal.
Key Points:
- CYTALUX is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal.
- CYTALUX serves as an adjunctive tool for surgeons to identify additional malignant ovarian cancer lesions that may have been missed by standard visual inspection and palpation, increasing the detection of more cancer during surgery.
- "We are excited about the potential impact CYTALUX can have for patients in their fight against ovarian cancer.
- CYTALUX, the Company's first product, received FDA approval for ovarian cancer in November 2021 and is being studied in the Phase 3 ELUCIDATE Trial for lung cancer in the US.